Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    11
ATC Name B/G Ingredients Dosage Form Price
A10BA02 DIANORM XR 500 G Metformin HCl - 500mg 500mg Tablet, film coated, extended release 349,399 L.L
H02AB02 DEXAMEDIS FORT G Dexamethasone Phosphate - 8mg/2ml 8mg/2ml Injectable solution 43,003 L.L
R06AX27 DELINE-MED G Desloratadine - 0.5mg/ml 0.5mg/ml Syrup 259,810 L.L
A10BA02 DIANORM XR 500 G Metformin HCl - 500mg 500mg Tablet, film coated, extended release 349,399 L.L
H02AB02 DEXAMETHASONE SODIUM PHOSPHATE USP - EIPICO G Dexamethasone (sodium phosphate) - 8mg/2ml 8mg/2ml Injectable solution 185,450 L.L
R06AX27 DESLAMED G Desloratadine - 0.5mg/ml 0.5mg/ml Solution 323,802 L.L
L01EL01 DULLARMA G Ibrutinib - 140mg 140mg Capsule, hard L.L
H02AB02 DEXASINA G Dexamethasone Phosphate - 8mg/2ml 8mg/2ml Injectable solution 3,471,145 L.L
R06AX27 DESLOR CHAPHA G Desloratadine - 0.5mg/ml 0.5mg/ml Solution 323,802 L.L
R06AX27 DESLORATADINE ARROW G Desloratadine - 0.5mg/ml 0.5mg/ml Solution 256,674 L.L
N06AX16 DEFAXINE G Venlafaxine (HCl) - 75mg 75mg Capsule, extended release 724,395 L.L
H02AB02 DEXAMETHASON-PANPHARMA G Dexamethasone - 5mg/1ml 5mg/1ml Injectable solution 368,213 L.L
N06AX16 DEPREVIX HELLAS G Venlafaxine - 75mg 75mg Capsule, prolonged release 564,414 L.L
H02AB02 DEXAMETHASONE MEDIS G Dexamethasone Phosphate - 4mg/1ml 4mg/1ml Injectable solution 1,154,361 L.L
N06AX16 DEPREVIX HELLAS G Venlafaxine - 75mg 75mg Capsule, prolonged release 564,414 L.L
N04BC07 DACEPTON G Apomorphine HCl - 30mg/3ml 30mg/3ml Injectable solution 13,404,432 L.L
A10BB12 DIAMERIL G Glimepiride - 1mg 1mg Tablet 130,545 L.L
N04BC07 DACEPTON G Apomorphine HCl Hemihydrate - 100mg/20ml 100mg/20ml Injectable solution 12,678,532 L.L
N06AX16 DEPREVIX HELLAS G Venlafaxine - 150mg 150mg Capsule, prolonged release 968,910 L.L
N06AX16 DEPREVIX HELLAS G Venlafaxine - 150mg 150mg Capsule, prolonged release 968,910 L.L
A10BB12 DIAMERIL G Glimepiride - 2mg 2mg Tablet 199,657 L.L
N06AX21 DULOXA 60 G Duloxetine HCl - 60mg 60mg Capsule, delayed release 831,903 L.L
A03FA03 DOMPERIDONE BIOGARAN G Domperidone - 10mg 10mg Tablet, coated 116,914 L.L
N06AX21 DULOXA 30 G Duloxetine HCl - 30mg 30mg Capsule, delayed release 716,716 L.L
R03AL02 DUOLIN RESPULES G Salbutamol (sulfate) - 2.5mg/2.5ml, Ipratropium bromide (monohydrate) - 500mcg/2.5ml Inhaltion solution with nebuliser 417,935 L.L
A10BB12 DIAMERIL G Glimepiride - 3mg 3mg Tablet 261,089 L.L
M01AX05 DONA G Glucosamine hemisulfate - 1500mg 1500mg Powder for solution 1,615,299 L.L
N06AX21 DULOXETINE BIOGARAN G Duloxetine HCl - 60mg 60mg Capsule, gastro-resistant 573,821 L.L
N06AX21 DULOXETINE BIOGARAN G Duloxetine HCl - 30mg 30mg Capsule, gastro-resistant 573,821 L.L
A03FA03 DOMIDONE CHAPHA SUGAR FREE G Domperidone - 5mg/5ml 5mg/5ml Suspension 319,963 L.L
    ...
    11
Sitemap
© Copyrights reserved to Ministry of Public Health 2025